How can I tell whether a treatment claim fits me?

Is it the same material my clinic offers?

Start with the plain name of what was used. Marrow concentrate begins with marrow taken from your pelvis. A machine spins it, keeping more of the cell-filled part. Prepared body fat goes through different steps. Donor tissue comes from another person.

Some studies use cells kept in a lab. The cells grow in number over days or weeks. That isn't the same as material prepared that day. Ask the clinic to name exactly what it offers. You'll then compare that name with the study.

The result won't fit when the products differ.

Was the study about my sore joint?

Most of this research concerns worn knees. A knee result won't answer a shoulder question. The cause of soreness must match too. A study about worn joint surfaces can't answer pain from nearby muscle.

Look for how many patients stayed until the final check. A big starting group doesn't help if many quit answering. You'll also check what each patient received. Some may get steroid medicine or simple fluid for comparison. Others may get PRP, which comes from your blood. Spinning leaves a part richer in platelets, tiny pieces that help a clot form.

You need the same joint and similar care.

Would I notice the reported change?

Studies often ask patients to rate pain or movement. A small change in that rating may look useful. Yet patients won't always notice it while walking. Ask whether the change was large enough to feel. Ask whether it lasted through the final check.

Also count the patients who stopped answering researchers. You can't know how their joints felt later. Read what side effects were found. Check whether people needed more care afterward.

You don't need to master every medical word. Ask the clinic to explain the useful change plainly. A study matters when its result fits daily life.

Sources

1. The International Society for Cell & Gene Therapy position statement holds that the acronym MSC should mean mesenchymal STROMAL cells and should only be called stem cells where rigorous in vitro and in vivo evidence of stemness exists for that specific preparation.

   Viswanathan S, et al. — Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy, 2019. DOI: 10.1016/j.jcyt.2019.08.002.

2. The 2018 AAOS/NIH consensus work group recommended that minimally manipulated mixed cell preparations be called CELL THERAPY rather than stem cell therapy, and that their untested and uncharacterised nature be clearly communicated to patients and the public, because stem cells have properties these preparations do not meet.

   Chu CR, et al. — Optimizing Clinical Use of Biologics in Orthopaedic Surgery: Consensus Recommendations From the 2018 AAOS/NIH U-13 Conference. J Am Acad Orthop Surg, 2019. DOI: 10.5435/JAAOS-D-18-00305.

3. 21 CFR 1271.10(a) sets the four criteria a human cell or tissue product must meet to be regulated SOLELY under section 361 of the Public Health Service Act: it must be minimally manipulated; intended for homologous use only, as reflected by labeling and advertising; not combined with another article beyond water, crystalloids or a preserving agent; and either have no systemic effect and not depend on the metabolic activity of living cells, or else be for autologous use, use in a close blood relative, or reproductive use.

   US Code of Federal Regulations, Title 21 — 21 CFR 1271.10 - Are my HCT/P's regulated solely under section 361 of the PHS Act. , 2004.

4. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.

5. A 2025 systematic review and meta-analysis of 8 randomized trials in 502 patients found intra-articular mesenchymal stem cells improved WOMAC scores versus control at 6 months (MD 7.44, 95% CI 1.45-13.42) and 12 months (MD 10.31, 95% CI 0.96-19.67), with wide confidence intervals and a small pooled sample.

   Cao M, et al. — Efficacy and safety of mesenchymal stem cells in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Res Ther, 2025. DOI: 10.1186/s13287-025-04252-2.

6. A 2025 meta-analysis of 73 double-blind placebo-controlled injection trials in 5,895 knee osteoarthritis patients found placebo responder rates above 50 percent at 1, 3 and 6 months, declining by 12 months - which is why any uncontrolled 'our patients improved' claim from a clinic is uninterpretable.

   Previtali D, et al. — Placebo response to intra-articular injections in knee osteoarthritis: magnitude, evolution over time, and influencing factors. A systematic review and meta-analysis with meta-regression. EFORT Open Rev, 2025. DOI: 10.1530/EOR-2025-0022.

7. A double-blind placebo-controlled trial of allogeneic culture-expanded adipose MSCs in stage III knee osteoarthritis kept blinding for 12 months and followed the treatment arm to 60 months, reporting only mild transient adverse events - but only 29 subjects completed, 8 of them in the placebo arm.

   Jafar H, et al. — Intra-articular allogeneic adipose-derived mesenchymal stromal cell injections for stage III knee osteoarthritis: a double-blind placebo-controlled trial with 60-month follow-up. Stem Cells Transl Med, 2026. DOI: 10.1093/stcltm/szag018.